17 results about "Artificial organ" patented technology

The invention discloses a hydrogel microsphere sorting method, an artificial organ preparation method, a system and a medium. The method comprises the following steps: acquiring a hydrogel microsphere image in the micro-fluidic chip; analyzing the hydrogel microsphere image through a neural network to obtain an analysis result; based on the analysis result, hydrogel microspheres wrapping the target cells are sorted out; the neural network comprises a feature extraction layer and a multi-scale joint output head, and the hydrogel microsphere image is processed by the multi-scale joint output head after being convolved by the feature extraction layer to obtain an analysis result. According to the method, the hydrogel microspheres wrapped with the target cells are accurately identified and sorted by using a droplet microfluidic technology, a standardized artificial organ can be prepared based on the sorted hydrogel microspheres, and the functional maturity and reliability of the artificial organ are remarkably improved.

The present invention relates to a method for functionalizing a biopolymer having an -OH group or an -NH2 group by reacting the biopolymer with at least one compound having at least one C=C bond or C≡C bond and containing a chromophore that absorbs UV-Vis radiation directly adjacent to this bond. The present invention also relates to a method for obtaining a solid biopolymer material by reversibly crosslinking the functionalized biopolymer obtained by the above method under UV-Vis light irradiation. Furthermore, the present invention relates to the use of functionalized biopolymers as support materials for 3D bioprinting, or as materials for manufacturing structures selected from spheroids, organoids, artificial organs, coatings, and tissue models.

The invention provides an egg white-sourced protein-based biological hydrogel as well as a preparation method and application thereof. The method comprises the following steps: separating and purifying ovomucoid in egg white by adopting an ethanol fractional precipitation method, and accurately controlling the final concentration of ethanol in a system in two ethanol precipitation processes, so that the final concentration a of ethanol in the system in the primary ethanol precipitation process and the final concentration b of ethanol in the system in the secondary ethanol precipitation process meet the condition that a is greater than or equal to 40 vol% and less than or equal to 62%; other miscellaneous proteins, salts and other small molecular impurities in the egg white can be removed, and the ovomucoid is efficiently separated and purified from the egg white; the modified ovomucoid obtained by covalently modifying the ovomucoid separated and purified by the method by using a modifier has the rheological characteristics of rapid crosslinking, shear thinning and the like, and can form the protein-based biological hydrogel under the action of a photoinitiator. The rapid prototyping and mechanical properties of the hydrogel are met, and the hydrogel has a wide application prospect in preparation of 3D biological printing materials, 4D biological printing materials, artificial organs, artificial tissues and dressings.

The application discloses a multifunctional artificial organ device, which comprises a shell, a blood pipe bundle and a hydrogel, the blood pipe bundle is contained in a containing cavity, the blood pipe bundle is communicated with a blood inlet and a blood outlet, the hydrogel is filled in the containing cavity, the hydrogel comprises a gel layer and allogeneic therapeutic cells, the allogeneic therapeutic cells are wrapped in the inside of the gel layer, and the allogeneic therapeutic cells absorb nutrient substances and oxygen separated from the blood pipe bundle and secrete therapeutic factors to the blood pipe bundle. The multifunctional artificial organ device in the embodiment of the application wraps the allogeneic therapeutic cells in the inside of the gel layer, so that the immune rejection of the human body is reduced, the human blood is filtered through the blood pipe bundle, the nutrient substances and oxygen are separated from the blood pipe bundle for normal metabolism of the allogeneic therapeutic cells, the allogeneic therapeutic cells generate therapeutic factors, the therapeutic factors flow to internal organs along with the blood, and the purpose of disease treatment is achieved.

The invention relates to a blood shearing device and a blood compatibility evaluation method. The blood shearing device comprises an objective table, a fixing support, a supporting beam, a stator, a rotor and a driving source. The device can simultaneously adjust the roughness and wettability of the material surface, breaks through the limitation that only a single factor can be researched in the prior art, and provides a more comprehensive platform for systematically evaluating the blood compatibility; in the experimental method, red blood cell hemolysis is detected, and the degradation condition of plasma protein is evaluated synchronously, so that the overall injury mode of blood components under the action of an artificial surface can be reflected more truly. Experimental basis can be provided for material selection and surface optimization of blood contact type medical instruments such as an artificial heart pump, an ECMO and a hemodialysis machine, the clinical complication risk can be reduced, and development of artificial organs and blood purification technologies is promoted.

To provide a reinforced decellularized and recellularized artificial organ graft by providing a method for sealing the decellularized and recellularized artificial organ graft.SOLUTION: A method of reducing the porosity of an outer fibrous layer of a decellularized mammalian organ or tissue or portion thereof, the method comprising contacting an exterior surface of a mammalian organ or tissue or portion thereof comprising a vascular tree and cells with a composition comprising at least one agent in an amount to form a coating on the exterior surface, wherein: Wherein the coating is effective to increase the retention of fluid in the organ or tissue relative to fluid introduced into the corresponding organ or tissue or portion thereof prior to exposure to the composition, and decellularizing the coated mammalian organ or tissue or portion thereof by perfusion decellularization.SELECTED DRAWING: None

The present invention relates to an artificial organ production system that utilizes a big data infrastructure. The artificial organ production system of the present invention includes an input unit that accepts user requirements for the artificial organ to be produced as input values, a database unit that stores data necessary for artificial organ production, a control unit that produces the artificial organ by inputting the input values ​​into an artificial organ production algorithm learned based on the database unit, and a bioprinter that produces the artificial organ under the control of the control unit.

The invention discloses a preparation method of an implantable artificial organ, the implantable artificial organ and application of the implantable artificial organ, and relates to the technical field of biomedical materials. The preparation method of the implantable artificial organ comprises the following steps: preparing zwitter-ion modified polyurethane from amphiphilic ion diol, monomer diol, diisocyanate, a catalyst, a chain extender and a reaction solvent through a solution polymerization method, dissolving the zwitter-ion modified polyurethane into a preparation solvent, and stirring to obtain the implantable artificial organ. The implantable artificial organ is prepared by a solution preparation method. According to the invention, bipolar ion diol is used as a hard segment, another monomer diol is used as a soft segment, and the influence of soft and hard segments with different molar ratios on the performance of the implantable artificial organ is studied. Wherein the hard segment can provide hydrophilicity, biocompatibility and antifouling property; the soft segment can provide flexibility and proper mechanical properties by regulating and controlling the molecular weight; diisocyanate is used as a chemical building block to connect soft and hard segments. The zwitter-ion modified polyurethane artificial blood vessel and heart valve prepared by the invention have good mechanical property, antifouling property and anticoagulation property, and the prepared artificial blood vessel also has the capability of resisting intimal hyperplasia and can keep unobstructed for a long time.

The present invention relates to a method for producing a highly functional artificial organ using aptamers, comprising blood vessels capable of transporting perfusate. When used as a coating agent for a decellularized scaffold, the aptamer according to the present invention enhances vascular adhesion, activity, and angiogenic potential, thereby enabling more effective vascular reconstruction than existing antibodies. Consequently, a vascularized artificial liver prepared using this aptamer reduces thrombosis in vivo and enhances liver function, and is therefore expected to be applicable to methods for treating diseases using artificial organs prepared using the aptamers according to the present invention.

The present invention relates to a method for producing a multi-tissue lung organoid structurally surrounded by fibroblasts, and a use thereof, and provides a three-dimensional structure composed of a lung organoid and a fibroblast layer surrounding the outside thereof. The organoid according to the present invention can maintain a high level of structural stability and bio-fidelity by reproducing a cell arrangement and microenvironment similar to those of actual lung tissue. The multi-tissue organoid more precisely reproduces a microenvironment in which epithelial tissues and interstitial tissues are arranged in layers as in a living body, rather than adopting a simple cell mixing method, and thus can be used in various biomedical applications, such as regenerative medicine, research on lung disease conditions, and evaluation of responsiveness to anticancer drugs and anti-fibrotic drugs. In addition, the present invention has excellent expandability to organoid-on-chip technology or bio-artificial organ development, and thus can be expected to be used as a precision medicine and next-generation cell therapy platform.

The invention relates to a method for functionalizing a biopolymer, in which a biopolymer having-OH or-NH2 groups is reacted with at least one compound containing at least one C = C or C = C bond and a UV-Vis radiation-absorbing chromophore directly adjacent to the bond. The invention also relates to a process for obtaining a solid biopolymer material, wherein the functionalized biopolymer obtained by the above process undergoes reversible crosslinking upon exposure to light in the UV-VIS range. The invention also relates to the use of the functionalized biopolymer as a support material for 3D bioprinting and to the use of the functionalized biopolymer for producing a structure selected from spheroids, organoids, artificial organs, envelopes and tissue models.

This invention belongs to the technical field of biomedical materials, artificial organs, and extracorporeal circulation support devices, and relates to a hydrophilic modified siloxane hollow fiber composite membrane, its preparation method, and its applications. The hydrophilic modified siloxane hollow fiber composite membrane consists of a porous hollow fiber base membrane and a dense hydrophilic organosilicon functional layer constructed on the outer surface of the porous hollow fiber base membrane. Based on the hydrophilic modified siloxane hollow fiber composite membrane, this invention further constructs a small membrane oxygenator based on this composite membrane, which can be used for extracorporeal circulation gas exchange and is suitable for establishing animal extracorporeal circulation models and preclinical experimental studies. This device features a compact structure, high gas exchange efficiency, low blood damage, and good operational stability.

Methods and compositions relating to at least partially recellularized human organs are provided herein. Various methods for decellularizing non-human animal organs and recellularizing the non-human animal extracellular matrix with cellular compositions. Furthermore, compositions and methods for treating liver disease or other diseases (such as acute liver failure) using an extracorporeal bioartificial liver or other organs are provided herein.

The application relates to a medicine preparation containing tryptanthrin for resisting biofilm formation of Acinetobacter baumannii and application thereof, and belongs to the technical field of biological medicine. The medicine preparation containing tryptanthrin for resisting biofilm formation of Acinetobacter baumannii contains tryptanthrin and dimethyl sulfoxide, and the Acinetobacter baumannii is selected from one of standard strains, drug-resistant strains and sensitive strains. The tryptanthrin in the medicine preparation can affect the development process of the biofilm, thereby inhibiting the biofilm of the Acinetobacter baumannii, and the tryptanthrin does not affect the growth of the bacteria, so that the drug resistance is not easily generated. When the concentration of the tryptanthrin is 20 mu g / mL, the effect of more than 50% of the biofilm being inhibited can be achieved without affecting the growth of the bacteria, so that the tryptanthrin as the biofilm inhibitor can be used as an anti-biofilm medicine in the clinic, and has a good application prospect as an anti-biofilm infection coating material of medical implant equipment and artificial organs.

Embodiments of the present disclosure are directed to a biomedical packaging system which may include an assembly / primary packaging having one chamber configured to hold liquid nutrient media, as well as a bio-artificial organ (BAO), and another chamber arranged adjacent to the first compartment configured to be substantially liquid-free. The system can further include a baffle including a port, configured to separate the first chamber from the second chamber, as well as a storage container / secondary packaging.

The present invention relates to a method for preparing an extracellular matrix-induced self-assembly-based 3D printed artificial tissue, and artificial tissue prepared thereby, and provides: a method in which a self-assembly, formed by inducing stem cell differentiation using extracellular matrix-derived biomaterials, is applied to 3D printing so that artificial tissue can be fine-patterned with widths in units of micrometers and morphological appearance of origin tissue can be implemented; and artificial tissue printed in a mature tissue form, which is not that of a cell-biomaterial mixture from the time of printing. The artificial tissue prepared by the preparation method of the present invention mimics the biological characteristics of a target organ according to the origin of the extracellular matrix, and thus enables artificial tissue and artificial organs very similar to actual original tissue to be provided.